A molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib - ELIOS

Study identifier:D5161C00003

ClinicalTrials.gov identifier:NCT03239340

EudraCT identifier:2017-002359-27

CTIS identifier:N/A

Study Complete

Official Title

A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib

Medical condition

EGFR mutation positive locally advanced or metastatic Non-Small Cell Lung Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Osimertinib

Sex

All

Actual Enrollment

154

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 30 May 2018
Primary Completion Date: 19 Sept 2023
Study Completion Date: 19 Sept 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria